JP2011521969A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521969A5
JP2011521969A5 JP2011511843A JP2011511843A JP2011521969A5 JP 2011521969 A5 JP2011521969 A5 JP 2011521969A5 JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011521969 A5 JP2011521969 A5 JP 2011521969A5
Authority
JP
Japan
Prior art keywords
composition
kinase
inhibitor
activin receptor
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011511843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521969A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/045607 external-priority patent/WO2009146408A1/en
Publication of JP2011521969A publication Critical patent/JP2011521969A/ja
Publication of JP2011521969A5 publication Critical patent/JP2011521969A5/ja
Pending legal-status Critical Current

Links

JP2011511843A 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 Pending JP2011521969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5746108P 2008-05-30 2008-05-30
US61/057,461 2008-05-30
PCT/US2009/045607 WO2009146408A1 (en) 2008-05-30 2009-05-29 Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions

Publications (2)

Publication Number Publication Date
JP2011521969A JP2011521969A (ja) 2011-07-28
JP2011521969A5 true JP2011521969A5 (enExample) 2011-09-08

Family

ID=41377599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511843A Pending JP2011521969A (ja) 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件

Country Status (5)

Country Link
US (1) US20100087486A1 (enExample)
EP (1) EP2285380A4 (enExample)
JP (1) JP2011521969A (enExample)
CN (1) CN102083439A (enExample)
WO (1) WO2009146408A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524073A (ja) * 2009-04-17 2012-10-11 スムマ ヘルス システムズ エルエルシー 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
BR112013003600A2 (pt) * 2010-08-17 2016-08-16 Allergan Inc agonistas ep2 ou ep4 para o tratamento de névoa da córnea
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
CA2909230C (en) 2013-04-12 2021-06-15 Kyoto University Method for inducing alveolar epithelial progenitor cells
JP6429280B2 (ja) 2013-05-14 2018-11-28 国立大学法人京都大学 効率的な心筋細胞の誘導方法
MX386503B (es) 2013-07-30 2025-03-19 Kyoto Prefectural Public Univ Corp Medicamentos terapeuticos de matriz extracelular endotelial corneal.
WO2015020113A1 (ja) 2013-08-07 2015-02-12 国立大学法人京都大学 膵ホルモン産生細胞の製造法
CN105849255A (zh) 2013-09-05 2016-08-10 国立大学法人京都大学 新的产多巴胺神经前体细胞诱导方法
WO2015064768A1 (ja) 2013-10-31 2015-05-07 京都府公立大学法人 角膜内皮の小胞体細胞死関連疾患治療薬
CN106536718B (zh) 2014-05-21 2021-04-27 国立大学法人京都大学 胰芽细胞的制造方法及含有胰芽细胞的胰疾病治疗剂
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
CN106282092A (zh) * 2016-09-07 2017-01-04 山东省眼科研究所 一种角膜内皮分离和扩增培养液
EP3633026A4 (en) 2017-05-25 2021-03-10 Kyoto University METHOD FOR INDUCING THE DIFFERENTIATION OF A MESODERMAL INTERMEDIATE CELL TO A KIDNEY PRECURSOR CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF A PLURIPOTENT STEM CELL FROM A KIDNEY PRECURSOR CELL
WO2019160148A1 (ja) 2018-02-19 2019-08-22 大日本住友製薬株式会社 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
JP7357369B2 (ja) 2018-07-23 2023-10-06 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
JP7700673B2 (ja) 2019-05-15 2025-07-01 味の素株式会社 神経堤細胞または角膜上皮細胞の純化方法
EP3974519A4 (en) 2019-05-20 2023-07-12 Ajinomoto Co., Inc. EXPANSION CULTURE METHOD FOR CARTILAGE OR BONE PRECURSOR CELLS
CA3152504A1 (en) 2019-09-06 2021-03-11 Keio University Method for producing cell aggregate including glial progenitor cells
CN118726239A (zh) 2019-10-01 2024-10-01 国立大学法人京都大学 输尿管芽顶端部细胞的分离方法
WO2021187602A1 (ja) 2020-03-19 2021-09-23 国立大学法人京都大学 心筋細胞の精製方法
KR102949854B1 (ko) 2020-03-19 2026-04-07 오리즈루 세라퓨틱스 가부시키가이샤 심근세포 정제 방법
US20230256024A1 (en) 2020-07-13 2023-08-17 Kyoto University Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
WO2022149616A1 (ja) 2021-01-08 2022-07-14 国立大学法人京都大学 ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法
CA3222761A1 (en) 2021-06-10 2022-12-15 Ajinomoto Co., Inc. Method for producing mesenchymal stem cells
AU2022294563A1 (en) 2021-06-17 2024-01-18 Kyoto University Method for producing cerebral cortical cell preparation derived from human pluripotent stem cells
US20240240157A1 (en) 2021-07-15 2024-07-18 Cellfiber Co., Ltd. Structure and Use Thereof
JPWO2023017848A1 (enExample) 2021-08-11 2023-02-16
JPWO2023149407A1 (enExample) 2022-02-01 2023-08-10
EP4477746A4 (en) 2022-02-09 2026-02-18 Racthera Co Ltd METHOD FOR EVALUATING THE DIFFERENTIATION POTENTIAL OF CELLS IN A CULTURE BROTH IN THE DIFFERENCE OF MULTIPOTENTED STEM CELLS INTO NEURAL CELLS OF THE MENSCEPHAL FLOOR PLAQUE REGION
JPWO2023228908A1 (enExample) 2022-05-23 2023-11-30
US20260097083A1 (en) 2022-09-26 2026-04-09 Kyoto University Method for producing pancreatic endoderm cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
CA2149528A1 (en) * 1993-09-29 1995-04-06 Billie M. York Compositions containing growth factors and antimetabolites
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
EP0670733A1 (en) * 1993-09-29 1995-09-13 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AU2002357003A1 (en) * 2001-12-28 2003-07-24 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US7361669B2 (en) * 2003-01-02 2008-04-22 Millennium Pharmaceuticals, Inc. Compositions and method for inhibiting TGF-β
US7189733B2 (en) * 2003-03-12 2007-03-13 Millennium Pharmaceuticals, Inc. Compositions and methods for inhibiting TGF-β
EP1633718B1 (en) * 2003-06-17 2012-06-06 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-s
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US7098222B2 (en) * 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20060234911A1 (en) * 2005-03-24 2006-10-19 Hoffmann F M Method of reversing epithelial mesenchymal transition
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
EP2044056B1 (en) * 2006-07-14 2012-08-22 Novartis AG Pyrimidine derivatives as alk-5 inhibitors
US7524640B2 (en) * 2006-08-06 2009-04-28 Children's Medical Center Corporation Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia

Similar Documents

Publication Publication Date Title
JP2009280627A5 (enExample)
DK2729123T3 (en) Cannabinoidreceptorbindende funds and formations and methods
CA2796575C (en) Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
JP2009102342A5 (enExample)
IL260579A (en) Diagnosis, prevention and treatment of joint diseases
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
EA202091303A2 (ru) Композиция ингибитора jak для местного применения
WO2007102241A1 (ja) 外用の医薬組成物
JP2014518266A5 (enExample)
CN102821791A (zh) 透皮递送贴剂
RU2013121788A (ru) Ингибиторы репликации вич
HRP20120254T1 (hr) Pripravak za produljenu lokalnu anesteziju koji sadrži saib
CN104379139A (zh) 贴附剂
TW201004617A (en) Anti-inflammatory analgesic agent for external use
CA2717948A1 (en) 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
TW201141524A (en) Stabilized ophthalmic galactomannan formulations
ES2457519T3 (es) Pasta a base de agua que contiene diclofenaco sódico
WO2009109654A3 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
CN105997951A (zh) 一种包含卡巴拉汀的透皮给药系统及制备方法
WO2014110353A8 (en) Notch ligand bound biocompatible substrates and their use in bone formation
CA2785242A1 (en) Carrier composition
CA2785851A1 (en) Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
JP2009532373A5 (enExample)
ITMI20071724A1 (it) Formulazioni topiche antivirali in forma di gel bioadesivo
WO2019089523A1 (en) Hydrophobic acid addition salts and pharmaceutical formulations thereof